newsimpactscreener

Articles Market Screenings Pricing Docs Blog Changelog Sign in Sign up

newsimpactscreener— news connected to markets.

@newsimpactscrnr on X @newsimpactscreener on Instagram Terms Privacy

newsimpactscreener

Articles Market Screenings Pricing Docs Blog ChangelogSign in Sign up

UK's GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion… · News Impact Screener

Back to The Tape

Reuters

09 Jun 2026, 06:04 UTC · 3h ago

UK's GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion

ShareX LinkedIn

Read original · https://www.reuters.com/business/healthcare-pharmaceuticals/uks-gsk-buy-us-based-cancer-drugmaker-nuvalent-106-billion-2026-06-09/

UK's GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion

GSK▲167%
biotech
m and a
NVLNT
acquisition
cancer drugs
pharma

Top 1 mover · tap to explore

Story key points

1 claims · impact-rated

What matters in this story

1
GSK has agreed to acquire cancer drug developer Nuvalent for $10.6 billion. — A multi-billion dollar acquisition indicates strategic expansion into oncology and is typically a positive catalyst for the target company's valuation.
+0.60

Ticker attribution

Model heads

Sentiment in this article

NVLNT+1.00
The company is being acquired for a significant sum of $10.6 billion.
GSK+0.30
The company is expanding its oncology portfolio through a strategic acquisition.

Relationships in this article

Continue reading

6 related stories

Next reads from the same story arc

CNBC
4h ago
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
- acquisition
- biotech
- cancer drugs
Read

→

acquirer

+1.00

[a_to_b] GSK agreed to acquire Nuvalent for $10.6 billion.

Early access

You’re reading about it. Someone else is already positioned.

News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.

NVLNT
GSK

Email address

Browse live screenings

Impact vectors

2 dimensions · 9 clusters

Analytical profile by cluster

Market Behaviour+1.000
Sector Rotation+0.200
Macro Sensitivity+0.000
Business Model+0.000
Financial Structure+0.000
Growth Profile+0.000
Valuation & Positioning+0.000
Geography & Trade+0.000
Supply Chain+0.000

Top impact dimensions

Short Squeeze Potential+1.000
Healthcare+0.200

Market reaction

10 bid · 0 offered

Most positively impacted

Bid

01
AHealthcare
+0.187
02
AAPGHealthcare
+0.187
03
AAWHHealthcare
+0.187
04
ABBVHealthcare
+0.187
05
ABOSHealthcare
+0.187
06
ABTHealthcare
+0.187
07
ABVXHealthcare
+0.187
08
ACADHealthcare
+0.187
09
ACHCHealthcare
+0.187
10
ACLXHealthcare
+0.187

Most negatively impacted

Offered

No stock impact ranking available yet.

Reuters

7h ago

GSK in talks to buy cancer biotech Nuvalent for more than $9 billion, FT reports

acquisition
biotech
cancer drugs

Read

Market Watch

1h ago

GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down

acquisition
biotech
m and a

Proactive Investors

2h ago

GSK agrees $10.6bn Nuvalent takeover to bolster oncology pipeline

acquisition
biotech
m and a

WSJ

2h ago

GSK to Buy Nuvalent for $10.6 Billion in Oncology Push

biotech
m and a
pharma

Proactive Investors

2h ago

Imaging Biometrics sees encouraging Phase 1 trial data

biotech
pharma